AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00920543
Drug: FP 100mcg
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Twice daily dosing
Trial: NCT00920543
Drug: FP 500mcg
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Twice daily dosing
Trial: NCT00920543
Drug: FP 250mcg
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Twice daily dosing
Trial: NCT04419506
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 milligram (mg) BI 1015550 taken orally as film-coated tablets (1x 6mg tablet, 1x 12 mg tablet) twice daily (36 mg daily), in the morning and in the evening for 12 weeks.
Trial: NCT02526849
Drug: Fecal microbiota transplantation (FMT)
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
Trial: NCT02734732
Drug: Trimethoprim/Sulfamethoxazole
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02734732
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00410371
Drug: Lamotrigine
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine
Trial: NCT00395044
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02842567
Drug: Hydroxytyrosol plus Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
Trial: NCT01748994
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg per day for four months
Trial: NCT02642861
Drug: Cyclobenzaprine
RxNorm normalized name: Cyclobenzaprine
DrugBank: Cyclobenzaprine (DB00924)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cyclobenzaprine administration for 2 weeks
Trial: NCT02642861
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate for 2 weeks
Trial: NCT03168061
Drug: NC 6300
RxNorm normalized name: NC-6300
DrugBank: NC-6300 (DB17341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
Trial: NCT02066662
Drug: Rivaroxaban or Marcumar
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR \> 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
Trial: NCT04086940
Drug: Esmolol
RxNorm normalized name: Esmolol
DrugBank: Esmolol (DB00187)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preventive
Trial: NCT02207387
Drug: Azilect
RxNorm normalized name: Azilect
DrugBank: Rasagiline (DB01367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
Trial: NCT00715715
Drug: Prednisone Priming
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
Trial: NCT04329949
Drug: Relacorilant, 100 mg and 25 mg
DrugBank: Relacorilant (DB14976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relacorilant is supplied as capsules for oral dosing.
Trial: NCT01181960
Drug: Risperidone long acting injectable - New Starts
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
Trial: NCT04329949
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
Trial: NCT01181960
Drug: Risperidone long acting injectable - Continuous Users
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
Trial: NCT02622932
Drug: Anlotinib and 14C-labeled Anlotinib
RxNorm normalized name: urea [14C]
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01037712
Drug: Valacyclovir (ZELITREX)
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g, 8g/day, 4 a day 23 weeks maximum.
Trial: NCT01505062
Drug: SAR421869
RxNorm normalized name: SAR421869
DrugBank: SAR421869 (DB17909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation: Sterile suspension for intraocular injection, 100 microliters (μL) aliquots in 0.3 milliliter (mL) type I borosilicate glass 'V' vials with a butyl stopper and aluminum crimp seal.~Route of administration: subretinal injection
Trial: NCT01181960
Drug: Paliperidone Palmitate -New and Continuous Users
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
Trial: NCT04346225
Drug: Hyperpolarized C13
RxNorm normalized name: SOR-C13
DrugBank: SOR-C13 (DB15366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by intravenous injection. When receiving two HP 13C pyruvate injections, the injections will be separated by a period of 15-60 minutes
Trial: NCT00188994
Drug: Insulin Cardioplegia
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04334148
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral self administered tablet
Trial: NCT03501212
Drug: Topical Anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA Cream 2.5 gr applied to both wrists
Trial: NCT00834119
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
Trial: NCT00834119
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
Trial: NCT01508676
Drug: Pennsaid
RxNorm normalized name: Pennsaid
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01565746
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
Trial: NCT01565746
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
Trial: NCT01565746
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
Trial: NCT01720667
Drug: Intravenous levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
Trial: NCT01720667
Drug: Intravenous phenobarbital
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous load of phenobarbital (20 to 40 mg/kg) following EEG confirmation of seizure activity load.
Trial: NCT00690872
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00690872
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00850499
Drug: fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
Trial: NCT00850499
Drug: rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rituximab 375mg/m2 on Day 1 of every 35-day cycle
Trial: NCT00850499
Drug: VELCADE
RxNorm normalized name: Velcade
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
Trial: NCT00722176
Drug: BL-1020
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg
Trial: NCT00722176
Drug: BL-1020 10-30 mg
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-1020 10-30 mg
Trial: NCT00722176
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: risperidone
Trial: NCT00247325
Drug: Iodixanol(Drug)
RxNorm normalized name: Iodixanol
DrugBank: Iodixanol (DB01249)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02558023
Drug: Urapidil
RxNorm normalized name: urapidil
DrugBank: Urapidil (DB12661)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urapidil (Eupressyl\*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.~The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.~Maximum dose of 30 mg.h-1.
Trial: NCT02558023
Drug: Nicardipine
RxNorm normalized name: Nicardipine
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine : IV~1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.~Maximum dose of 6 mg.h-1
Trial: NCT02614794
Drug: tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg orally twice daily
Trial: NCT02614794
Drug: trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg intravenously (IV) on Day 1 of Cycle 1, followed by 6 mg/kg on Day1 of each 21-day cycle. In regions where approved, trastuzumab may be given at 600mg subcutaneously once every 3-weeks at either study initiation or crossing over from previous IV trastuzumab.
Trial: NCT00552305
Drug: lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
Trial: NCT03426969
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03426969
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03426969
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT03426969
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV or PO
Trial: NCT02512796
Drug: Gadolinium contrast dye
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadolinium contrast dye administered during MRI
Trial: NCT00172380
Drug: Docetaxel Plus CDDP
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 36mg/m2 and cisplatin 75mg/m2
Trial: NCT03322657
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neostigmine injection
Trial: NCT03322657
Drug: Glycopyrrolate
RxNorm normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate injection
Trial: NCT03322657
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sugammadex injection
Trial: NCT02436239
Drug: Vilazodone
RxNorm normalized name: Vilazodone
DrugBank: Vilazodone (DB06684)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vilazodone tablets, once daily, oral administration
Trial: NCT00519532
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patches:~10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)~Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h
Trial: NCT02984475
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00005037
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005037
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide capsule once a day for 42 days every 10 weeks.
Trial: NCT00069121
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 130 mg/m\^2 intravenous (IV) infusion over two hours on Day 1 of each 3-week cycle.
Trial: NCT00069121
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered by one of two regimens, as specified in the arm description.
Trial: NCT02354001
Drug: Raloxifene hydrochloride
RxNorm normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 120mg daily- 1 capsule for 12 week trial
Trial: NCT01115712
Drug: Comparator: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg once daily
Trial: NCT02427581
Drug: Poly ICLC
RxNorm normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00055198
Drug: daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02551848
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT01426386
Drug: FE 999049
RxNorm normalized name: Fe
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01426386
Drug: Gonal - F
RxNorm normalized name: Gonal F
DrugBank: Follitropin (DB00066)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01457339
Drug: SPD489 (Lisdexamfetamine dimesylate)
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
Trial: NCT02660658
Drug: Intrathecal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
Trial: NCT02730247
Drug: ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
Trial: NCT02730247
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
Trial: NCT00950417
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00565422
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/day
Trial: NCT00097266
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets, oral, 15-30 mg, once daily, 12 weeks.
Trial: NCT00097266
Drug: Haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, oral, 5-15 mg, once daily, 12 weeks.
Trial: NCT01096667
Drug: Placebo to Ertuglilflozin 1 or 5 mg
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Placebo to ertuglilflozin tablet 1 or 5 mg once daily for 28 days
Trial: NCT01096667
Drug: Ertugliflozin 1 mg
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin tablet 1 mg once daily for 28 days
Trial: NCT01096667
Drug: Ertugliflozin 5 mg
RxNorm normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin tablet 5 mg once daily for 28 days
Trial: NCT01096667
Drug: Ertugliflozin 25 mg
DrugBank: Ertugliflozin (DB11827)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ertugliflozin tablet 25 mg once daily for 28 days
Trial: NCT01096667
Drug: HCTZ 12.5mg
RxNorm normalized name: HCTZ 12.5MG/LOSARTAN 50MG TAB
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocholorthiazide (HCTZ) 12.5 mg capsule once daily for 28 days
Trial: NCT00542984
Drug: teriparatide 20 micrograms/day subcutaneous
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00542984
Drug: salmon calcitonin 100 IU/day subcutaneous
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02522377
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inter venous injections
Trial: NCT02522377
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: inter venous injections
Trial: NCT04771715
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Trial: NCT04771715
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Trial: NCT04771715
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Trial: NCT04771715
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.
Trial: NCT04771715
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical records are reviewed to identify participants who received at least one dose of regorafenib plus a PD-1 inhibitor (nivolumab/pembrolizumab/camrelizumab/sintilimab/toripalimab/tislelizumab) in routine medical care.